Restricted Expression of an Adenoviral Vector Encoding Fas Ligand (CD95L) Enhances Safety for Cancer Gene Therapy
Open Access
- 30 June 2000
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 1 (6) , 555-565
- https://doi.org/10.1006/mthe.2000.0076
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching systemGene Therapy, 1998
- Adenovirus-Mediated Expression of Fas Ligand Induces Hepatic Apoptosis after Systemic Administration and Apoptosis ofEx Vivo-Infected Pancreatic Islet Allografts and IsograftsHuman Gene Therapy, 1997
- Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in MiceScience, 1996
- Fas Ligand-Induced Apoptosis as a Mechanism of Immune PrivilegeScience, 1995
- Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.The Journal of Experimental Medicine, 1995
- A role for CD95 ligand in preventing graft rejectionNature, 1995
- Fas(CD95)/FasL interactions required for programmed cell death after T-cell activationNature, 1995
- Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomasNature, 1995
- Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)Nature, 1995
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993